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Abstract  
 
RNA  helicases  are a large family of proteins that  are  able to unwind RNA duplex and remodel the structure  of RNA-protein (RNP) complexes  
using energy derived from hydrolysis of nucleotide triphosphates (NTPs). Every step of cellular RNA metabolism involves the activity of RNA 
helicases. Not surprisingly, more and more RNA helicases are reported to participate in the replication of viruses including the human 
immunodeficiency virus type 1 (HIV-1). Here, we provide evidence that overexpression of an RNA helicase named DHX30 enhances HIV-1 gene 
expression,  but  leads to the generation  of  viruses  that  package significantly low  levels of  viral RNA and exhibit  severely  decreased  infectivity. 
These  data  reveal  the  complex  roles  of  DHX30  in  HIV-1 replication and  implicate an inhibitory  activity of  DHX30  in HIV-1 RNA packaging.  
                    © 2007 Elsevier Inc. All rights reserved.  
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Introduction 
 
Human immunodeficiency virus type 1 (HIV-1) is a member  
of the lentivirus family. Each HIV-1 particle contains two copies  
of the full-length viral genomic RNA. Replication of viral RNA  
involves a series of discrete steps (Frankel and Young, 1998).  
Immediately after virus entry into the host cell, viral RNA is  
converted to viral cDNA by viral reverse transcriptase. Viral  
cDNA is then translocated to the nucleus and integrated into host  
chromosomal DNA with the help of viral integrase. Expression  
of HIV-1 RNA from the integrated viral cDNA depends on  
cellular machineries that carry out transcription, splicing,  
nuclear export and translation. Notably, HIV-1 encodes proteins  
to regulate these processes, including Tat and Rev. When viral  
structural proteins Gag, Gag-Pol and Env are produced, the full- 
length viral RNA is selectively packaged into virus particles by  
virtue  of  its  high affinity for viral Gag protein (Berkowitz et al., 
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1996). While going through all these processes, viral RNA needs  
to have its structure constantly rearranged. Some of these events  
are undertaken by viral nucleocapsid (NC) protein that has  
potent RNA chaperone activity and is involved in a number of  
important viral processes including reverse transcription and  
viral RNA packaging (Levin et al., 2005). In addition, recent  
studies have shown that cellular RNA helicases play a role in  
HIV-1 RNA metabolism (Jeang and Yedavalli, 2006). 
RNA helicases are a large family of proteins that are able to  
hydrolyze  nucleotide  triphosphates  and  use  the  energy  to  
unwind RNA secondary structures and to remodel the RNP  
complexes (Cordin et al., 2006; Tanner and Linder, 2001). The  
NTPase activity enables RNA helicases to rearrange RNA  
structures in a way that cannot be accomplished by RNA  
binding proteins such as HIV-1 NC. Therefore, although not  
carrying its own RNA helicases, HIV-1 needs to assimilate  
cellular RNA helicases to replicate viral RNA. One example is  
DDX3 that interacts with Rev and regulates the nuclear export  
of unspliced and singly spliced HIV-1 RNA (Yedavalli et al.,  
2004). DDX1 also binds to Rev and may function together with  
DDX3 to promote viral RNA export (Fang et al., 2005, 2004).  
Overexpression of  another  RNA helicase named  RH116 results  
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in increased levels of unspliced and singly spliced HIV-1 RNA,  
suggesting a role of RH116 in HIV-1 RNA expression at the  
post-transcriptional step (Cocude et al., 2003). The Werner  
syndrome helicase interacts with HIV-1 Tat protein, helps to  
recruit the transcription factors PCAF (p300/CREB-binding  
protein-associated factor) and p-TEFb (positive transcription  
elongation factor b) to HIV-1 LTR promoter and is indispens- 
able for transactivation of HIV-1 LTR (Sharma et al., 2007). The  
requirement of RNA helicases for HIV replication is further  
illustrated by the multiple activities of RHA (RNA helicase A)  
in HIV-1 gene expression and virus assembly. Studies show that  
RHA binds to the TAR (Tat transactivation region) structure at  
the 5′ end of HIV-1 RNA and stimulates transcription from the  
LTR promoter (Fujii et al., 2001). Overexpression of RHA  
enhances both RRE (Rev response element)/Rev- and CTE  
(constitutive transport element)-dependent Gag production; this  
indicates the involvement of RHA in the post-transcription step  
of viral gene expression (Li et al., 1999). It was recently  
reported that RHA is specifically packaged into HIV-1 particles  
and plays a role in viral reverse transcription (Roy et al., 2006).  
These findings begin to shed light on the active involvement of  
cellular RNA helicases in HIV-1 replication especially at the  
stage of viral gene expression. 
In the present study, we have investigated the potential effects  
of the DHX30 RNA helicase on HIV-1 replication. DHX30  
bears the DEVH signature motif and belongs to the DExD/H  
family that comprise the largest number of RNA helicases  
(Tanner and Linder, 2001). We observed that overexpression of  
DHX30 increased production of viral Gag proteins and the yield  
of virus particles. This effect of DHX30 was further shown as a  
result of its ability to enhance HIV-1 transcription. Interestingly  
though, overexpression of DHX30 severely inhibited the pack- 
aging of HIV-1 RNA into virus particles and caused significant  
reduction in viral infectivity. These data provide evidence that  
HIV-1 RNA packaging is not only regulated by viral NC protein  
but also modulated by cellular RNA helicases such as DHX30. 
 
Results 
 
Overexpression of DHX30 augments HIV-1 production 
 
DHX30 has three isoforms. Isoform 1 is 39 amino acids  
longer  than  isoform  2  at  the  N-terminus. Isoform 3 is the 
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shortest, lacking the helicase core domain, thus was not pursued  
in this study. The domain structure of DHX30(v2) is illustrated  
in Fig. 2A. We have attached the HA tag to the C-termini of  
DHX30(v1)  and  DHX30(v2)  cDNA  and  cloned  the  DNA  
fragments into the pcDNA3.1 expression vector. When 293T  
cells  were  transfected  with  the DHX30(v1)-HA and DHX30 
(v2)-HA DNA, the DHX30(v1)-HA protein was expressed at  
significantly lower levels than DHX30(v2)-HA (data no shown).  
We thus proceeded to investigate the effects of DHX30(v2)-HA  
on HIV-1 replication. Toward this end, various amounts of  
DHX30(v2)-HA  DNA were  co-transfected  with  the  HIV-1  
proviral  DNA  clone  BH10 into  293T cells.  Expression of  
DHX30(v2)-HA and viral Gag proteins was assessed in Western  
blot. The results of Fig. 1B reveal increased expression of the  
DHX30(v2)-HA protein in a dose-dependent manner. Levels of  
viral Gag protein in cells were evidently increased when more  
DHX30(v2)-HA proteins were expressed (Fig. 1B). This was  
reflected by the gradually increased levels of viruses in the  
supernatants as determined by Western blot and ELISA  
(Fig. 1B). The same experiments were repeated in HeLa cells  
using the HIV-1 proviral DNA clone NL4-3 and the levels of  
Gag protein in the cell lysates and the culture fluids were  
quantified by ELISA (Fig. 1C). Again, the increase of Gag  
expression in cells and in the culture fluids was observed with  
more DHX30(v2)-HA DNA used in transfection. 
We next asked whether the helicase activity is required for  
DHX30 to stimulate HIV-1 production. DHX30 belongs to the  
DExD/H helicase family and harbors the DEVH motif that is  
essential for the helicase activity (Cordin et al., 2006). We  
therefore changed the DEVH sequence to AAVH and created  
the  DHX30(AAVH)-HA  mutant.  Expression  of  DHX30  
(AAVH)-HA was detected in Western blot using anti-HA anti- 
bodies (Fig. 1D). As opposed to the effect of wild type DHX30,  
overexpression of the DHX30(AAVH)-HA mutant failed to  
stimulate the production of HIV-1 as shown by the data of  
ELISA of both cell lysates and culture supernatants (Fig. 1D). 
In order to determine whether DHX30 affects HIV-1 pro- 
duction at the transcriptional or translational level, total RNA  
was extracted from 293T cells that had been co-transfected with  
the DHX30 and BH10 DNA followed by Northern blot assay  
using HIV-1 DNA probes. The results of Fig. 1E show that the  
levels of both unspliced and spliced HIV-1 RNA increased with  
more  DHX30 DNA used  in transfection. The increased  levels of  
 
 
Fig. 1. Overexpression of DHX30(v2)-HA enhances HIV-1 Gag expression and virus production. (A) Illustration of the domain structures of DHX30(v2). dsRBD  
denotes double-stranded RNA binding domain. The signature motifs GKT, DEVH and SAT are highlighted. (B) Different amounts of DHX30(v2)-HA together with  
200 ng HIV-1 cDNA clone were used to transfect 293T cells. Expression of DHX30(v2)-HA was detected in Western blot using anti-HA antibodies. Levels of HIV-1  
Gag protein were measured by Western blot using anti-p24 antibodies. β-Actin was detected to monitor sample loading. Amounts of viruses in the supernatants were  
determined by HIV-1 p24 in ELISA. Similar results were obtained in three independent transfections. (C) The DHX30(v2)-HA DNA was co-transfected with 200 ng  
HIV-1 cDNA clone into HeLa cells. Expression of the DHX30(v2)-HA protein was detected by Western blot using anti-HA antibodies. Levels of Gag protein in cell  
lysates and the culture fluids were measured by HIV-1 p24 ELISA. Results from three independent transfection experiments are summarized in the bar graph. The  
standard deviations are shown and the calculated p values are indicated (** denotes p<0.05). (D) Overexpression of the DHX30(AAVH)-HA mutant does not affect  
HIV-1 production. 293T cells were transfected with 200 ng BH10 DNA and different amounts of DHX30(AAVH)-HA DNA. Expression of the DHX30(v2)-HA  
mutant was detected in Western blot using the anti-HA antibodies. The amounts of Gag protein in cells and the supernatants were determined in ELISA. The results  
from three independent transfections are summarized in bar graph. (E) Effects of DHX30(v2)-HA overexpression on HIV-1 RNA expression. Following co- 
transfection with the BH10 DNA and different amounts of the DHX30(v2)-HA DNA, total RNA was extracted from 293T cells and analyzed in Northern blot. HIV-1  
RNA was detected with HIV-1 DNA probe spanning nt positions 1 to 2000. The DHX30(v2)-HA mRNA was also detected to indicate its increased levels with more  
DHX30(v2)-HA DNA used in the transfection. The GAPDH mRNA was detected with the GAPDH DNA probe, the results served as internal controls.  
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DHX30 mRNA  were also  shown  by the  results of  Northern stability. Taken together, the  data suggest  a role of DHX30 in 
blots (Fig. 1E). The  elevated   levels  of  HIV-1 RNA  can  be HIV-1 gene expression. This  function  of DHX30 requires the 
ascribed   to   increased  RNA  expression  or  improved  RNA DEVH motif that is essential for the protein's helicase activity. 
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Overexpression of DHX30 increases basal transcription from the 
HIV-1 LTR promoter 
 
We next  investigated  whether  DHX30  overexpression  
promotes the expression of HIV-1 RNA by activating HIV-1  
LTR-dependent transcription. To this end, 293T cells were co- 
transfected with different amounts of DHX30(v2)-HA DNA  
together with the LTR-Luc reporter. The expressed DHX30(v2)- 
HA protein was detected in Western blots (Fig. 2A). Another  
reporter  DNA  named  TK-RL  was  also  included  in the trans- 
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fection procedure. The expression of Renilla luciferase from the  
TK-RL DNA was not affected by overexpressed DHX30 (data  
not shown). Therefore, levels of Renilla luciferase activity were  
used as internal controls to normalize transfection efficiency.  
The results of Fig. 2A show that levels of firefly luciferase  
activity from the LTR-Luc DNA gradually increased with more  
DHX30(v2)-HA  DNA  used  in  transfection.  The  results  of  
Northern blots further demonstrated that the overexpressed  
DHX30(v2)-HA protein raised the levels of firefly luciferase  
mRNA that had been transcribed from the HIV-1 LTR promoter  
(Fig. 2B). In order to determine whether this effect of DHX30 is  
specific  for  HIV-1 LTR-dependent  transcription,  the  same  
experiments were performed with another reporter DNA named  
GL3-Luc in which expression of the firefly luciferase is driven  
by the SV40 promoter (Rackham and Brown, 2004). In this  
case, no difference in the expression of firefly luciferase was  
observed either in the absence or the presence of DHX30(v2)- 
HA expression (Fig. 2C). 
HIV-1 encodes a regulatory protein Tat that transactivates  
LTR-dependent  transcription.  We  therefore  asked  whether  
DHX30 exerts any effect on the transactivation activity of Tat.  
The data of Fig. 2A show that Tat itself activated luciferase  
expression by approximately 5-fold. Levels of luciferase activity  
were further increased in the presence of overexpressed DHX30.  
Taken into account the elevated basal transcription activity of  
LTR due to exogenously expressed DHX30, the fold of trans- 
activation by Tat remained more or less constant (Fig. 2A).  
Therefore, overexpression of DHX30 stimulates HIV-1 gene  
expression by increasing the basal LTR transcription rather than  
by modulating the transactivation activity of Tat protein. We  
further tested the DHX30(AAVH)-HA mutant in the above co- 
transfection experiments to determine whether the observed  
activation effect of DHX30 depends on its helicase activity. The  
results revealed that production of firefly luciferase from HIV-1  
LTR  was  not  affected  by  the  DHX30(AAVH)-HA  protein  
(Fig. 2D). 
 
 
Fig. 2. Overexpression of DHX30(v2)-HA stimulates transcription from HIV-1  
LTR. (A) Effect of DHX30(v2)-HA overexpression on HIV-1 LTR-dependent  
transcription. 100 ng HIV-1 LTR-Luc reporter DNA together with different  
amounts of the DHX30(v2)-HA DNA was used to transfect 293T cells. 100 ng  
TK-RL  DNA was  also  included  in  transfection  to  normalize  transfection  
efficiency between samples. Expression of DHX30(v2)-HA was assessed in  
Western blot using anti-HA antibodies. The ratios of firefly luciferase (FL)  
activity vs the Renilla luciferase (RL) activity were calculated and the values  
represent the expression levels from HIV-1 LTR. 50 ng HIV-1 Tat vector DNA  
was used in the above co-transfection studies to determine the effects of DHX30 
(v2)-HA overexpression on Tat function. Standard deviations are shown and the  
calculated p values are indicated (** denotes p<0.05). (B) Levels of firefly  
luciferase mRNA were measured by Northern blot using [32P]-labeled firefly  
luciferase DNA as probes. The GAPDH mRNA was also detected to monitor  
sample loading. (C) Effect of DHX30(v2)-HA overexpression on transcription  
from the SV40 promoter. Different amounts of the DHX30(v2)-HA DNA  
together with 100 ng GL3-Luc DNA and 100 ng TK-RL DNA were used to  
transfect 293T cells. Levels of luciferase activity expressed from the SV40  
promoter were measured 24 h after transfection and the results are summarized  
in the bar graph as FL/RL ratios. (D) Overexpression of the DHX30(AAVH)-HA  
mutant  does  not  affect  HIV-1 transcription.  The  same  experiments  were  
performed as described in (A) except that the DHX30(AAVH)-HA DNA was  
used in the co-transfection experiments.  
 
 
 
 
Y. Zhou et al. / Virology 
 
Knockdown of DHX30 does not markedly affect expression of 
firefly luciferase from HIV-1 LTR 
 
We next investigated whether knockdown of DHX30 using  
siRNA oligos exerts any effect on the transcription activity of  
HIV-1 LTR promoter. Two siRNA oligos named siDHX30-1  
and siDHX30-2 were designed to target DHX30 mRNA at  
nucleotide positions 330 to 348 and 1133 to 1151, respectively.  
Both oligos efficiently down-regulated the levels of DHX30  
mRNA as shown by the results of Northern blots (Fig. 3A).  
When the LTR-Luc reporter DNA was transfected into cells that  
had been either treated with the control siRNA (siCon) or the  
siDHX30-1 and siDHX30-2 RNA, levels of firefly luciferase  
expression were not significantly affected (Fig. 3B). The same  
observation applies to the expression of firefly luciferase in the  
presence of HIV-1 Tat protein (Fig. 3B). These data suggest that  
decrease of the endogenous levels of DHX30 does not markedly  
affect gene expression from HIV-1 LTR promoter, which is  
likely a result of the compensation of the depleted DHX30 by  
other cellular RNA helicases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Effects of DHX30-knockdown on the expression of firefly luciferase  
from HIV-1 LTR. (A) Two siRNA oligos named siDHX30-1 and siDHX30-2  
were used to knockdown DHX30. Levels of DHX30 mRNA were measured by  
Northern blots using [32P]-labeled DHX30 cDNA as probes. The GAPDH  
mRNA was also detected as internal control. (B) Expression of firefly luciferase  
from  HIV-1  LTR.  After  transfection  with  the  control  siRNA (siCon)  or  
siDDX30-1 and siDDX30-2 (40 nM), 293T cells were co-transfected with the  
LTR-Luc (100 ng/well) and TK-RL (100 ng/well) DNA in the absence or  
presence of HIV-1 Tat protein (50 ng). Levels of firefly luciferase expression  
were adjusted to the Renilla luciferase activity and shown in the bar graph. 
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DHX30 is located within both the cytoplasm and the nucleus 
 
In order to investigate the subcellular localization of DHX30,  
we created the DHX30(v2)-RFP DNA construct and transfected  
HeLa cells with it. The results of confocal microscopy showed  
that the DHX30(v2)-RFP protein located in both the cytoplasm  
(indicated by open arrowheads) and the nucleus, with a main  
distribution in the nucleus under our experimental conditions  
(Fig. 4). This nuclear location supports the activation role of  
DHX30 in transcription from HIV-1 LTR promoter as shown by  
the results in Fig. 2. It is noted that DHX30(v2)-RFP exists in  
the granular and patchy patterns within the nucleus (Fig. 4); this  
suggests that DHX30 may associate with certain subnuclear  
structures that have been previously identified (Handwerger and  
Gall, 2006). We therefore performed immunostaining experi- 
ments to visualize three major subnuclear structures including  
the nucleolus with anti-fibrillarin antibody, the nuclear speckles  
(or spliceosomes) with anti-SC35 antibody, and the cajal bodies  
with anti-coilin antibody. The results of Fig. 4 show that some  
DHX30 were located to the nucleoli. DHX30 also exhibited  
partial co-localization with the spliceosome marker SC35, but  
barely overlapped with the cajal bodies (Fig. 4). It is noted that a  
population of the nuclear DHX30 did not reside in any of the  
above three subnuclear structures. These observations applied  
to over 90 out of the 100 cells that had been examined under  
confocal microscope. It is known that nucleoli and spliceo- 
somes are nuclear sites where active RNA transcription and  
splicing  take  place.  Co-localization  of  DHX30 with  these  
two subnuclear structures indicates a role of DHX30 in the  
events that take place in these special structures such as RNA  
processing. 
Overexpression of DHX30 severely restricts HIV-1 RNA 
packaging 
We next investigated whether overexpression of DHX30  
affects virus infectivity. The culture fluids of 293T cells that had  
been co-transfected with the HIV-1 proviral DNA BH10 and the  
DHX30(v2)-HA DNA were first clarified at 3000×g for 30 min  
at 4 °C to remove cell debris. Levels of viruses were quantified  
in HIV-1 p24 ELISA. Viruses equivalent to 10 ng of p24 were  
first treated with DNase I (1 unit/μl) to remove the BH10 DNA  
that had been used in transfection followed by infecting the  
TZM-bl indicator cells that are stably transfected with HIV-1  
LTR-Luc  DNA and express the CD4, CXCR4 and CCR5  
receptors (Wei et al., 2002). Infectivity of the viruses is deter- 
mined by measuring the levels of firefly luciferase activity in  
the infected TZM-bl cells. The results of Fig. 5A show that  
overexpression of DHX30(v2)-HA reduced virus infectivity by  
up to six-fold when 1 µg of DHX30(v2)-HA DNA was used in  
co-transfection. 
In order to identify the defects underlying the decreased virus  
infectivity, RNA was extracted from viruses and the levels of  
viral genomic RNA were determined in real-time RT-PCR.  
RNA samples were treated with DNase I prior to reverse tran- 
scription reaction in order to remove any possible contamina- 
tion  by  HIV-1 DNA. Primers were  designed to amplify the viral  
 
 
 
 
102 Y. Zhou et al. / Virology 372 (2008) 97-106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Subcellular localization of DHX30(v2). HeLa cells were transfected with the DHX30(v2)-RFP DNA followed by immunostaining with antibodies against 
fibrillarin, SC35 or coilin that serve as markers for the nuclear structures including nucleolus, nuclear speckles and cajal bodies, respectively. The nuclei were stained with 
TO-PRO3 and pseudo-colored as blue. The merged images are enlarged to clearly visualize the co-localization of DHX30(v2)-RFP with fibrillarin or SC35. The open 
arrowheads indicate the cytoplasmic DHX30(v2)-RFP. Co-localization of DHX30(v2)-RFP with fibrillarin or SC35 is indicated by filled arrowheads. The images shown 
represent the major phenotypes seen in one hundred transfected cells examined under confocal microscope.  
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nucleic acid sequence from  nt 675 to 960 that is present only in confirmed  by  th  data  of real-time  PCR   showing  a  10-fold 
the  viral genomic RNA not  in the  spliced ones. The results  of reduction of viral  RNA packaging when 1 µg of DHX30  DNA 
regular  PCR showed a  significant decrease in viral RNA levels was used in co-transfection (Fig. 5B). This significant reduction 
with   DHX30  overexpressed  (Fig. 5B).  This  observation  was in virion-associated  viral  RNA   is  not  a  result  of  decreased 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Effects of overexpression of DHX30(v2)-HA on HIV-1 infectivity and viral RNA packaging. (A) DHX30(v2)-HA overexpression decreases virus infectivity.  
The virus stocks used in the following infection studies and RNA packaging analysis are from transfection experiments shown in Fig. 1A. Viruses equivalent to 10 ng  
of p24 were used to infect the TZM-bl indicator cells. Results shown are the average of luciferase activities from three independent infections. Standard deviations are  
shown and the calculated p values are indicated (** denotes p<0.05). (B) Overexpression of DHX30(v2)-HA diminishes the packaging of HIV-1 RNA. RNA was  
extracted from viruses equivalent to 25 ng of p24. After treatment with DNase I, RNA samples were subject to reverse transcription using the p960-A primer. Regular  
PCR was performed with primers p675-S/p960-A for 25 cycles. Viral RNA samples were also directly assessed in PCR in order to rule out any contamination from  
HIV-1 DNA. A series of dilutions of BH10 DNA were included in PCR to indicate the linear range of the reactions. The results of real-time PCR were shown with the  
value of the control (0 µg of DHX30(v2)-HA) experiment arbitrarily set as 100. The averages from three independent experiments are shown in the bar graph. Standard  
deviations  are  shown  and  the  calculated  p  values  are  indicated  (** denotes  p< 0.05).  The  copy  numbers  from   one   real-time PCR experiment  were  also  presented.                   
(C) Levels  of  HIV-1  RNA in cells  were  assessed  in  Northern blots. (D) Overexpression  of  DHX30(v2)-HA  was  detected in Western blot using anti-HA antibodies.  
(E) Overexpression of the DHX30(AAVH)-HA mutant does not markedly affect HIV-1 RNA packaging. (F) Overexpression of DHX30(AAVH)-HA was detected in 
Western blot using anti-HA antibodies.  
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expression of HIV-1 RNA in cells as shown by the data of 
Northern blots (Fig. 5C). Overexpression of the DHX30(v2)- 
HA protein was monitored by Western blots using the anti-HA 
antibodies (Fig. 5D). In contrast, overexpression of the DHX30 
(AAVH)-HA mutant did not markedly alter viral RNA pack- 
aging (Figs. 5E, F). Collectively, overexpression of DHX30 
severely reduces packaging of viral RNA and, as a result, 
abrogates virus infectivity. 
 
Discussion 
 
Two RNA helicases have been reported to regulate HIV-1  
RNA transcription. One is RHA whose overexpression in 293T  
cells leads to increased HIV-1 LTR-dependent transcription  
(Fujii et al., 2001). RHA exerts this effect through binding to the  
TAR RNA structure with its second double-stranded RNA  
binding domain (dsRBD). The underlying mechanisms may  
either involve direct interaction of RHA with RNA polymerase II  
or the recruitment of transcription factors. In support of the latter  
possibility, RHA has been shown to interact with transcription  
factors CBP (CREB-binding protein) and BRCA1 (breast cancer  
specific tumor suppressor protein 1) (Anderson et al., 1998;  
Nakajima et al., 1997). Another example is the Werner syndrome  
helicase that interacts with Tat protein and is essential for the  
transactivation of HIV-1 LTR promoter (Sharma et al., 2007).  
Our studies suggest that the DHX30 RNA helicase is also  
involved in HIV-1 RNA transcription. This activity of DHX30 is  
specific for HIV-1 LTR since overexpression of DHX30 does not  
affect the expression of luciferase from either the herpes simplex  
virus 1 thymidine kinase promoter (in the TK-RL DNA) or the  
SV40 promoter (in the GL3-Luc DNA) (Fig. 2). Our data further  
demonstrate that DHX30 is not required for the function of Tat  
and its effect on HIV-1 transcription depends on the protein's  
helicase activity. 
It  is  unclear  how  DHX30  stimulates  transcription from HIV- 
1 LTR promoter. One clue is the existence of a putative type A  
dsRBD at the N-terminus of DHX30 spanning amino acids 14  
to 82 (Fig. 1A). It is plausible that DHX30 binds to the TAR  
RNA via this putative dsRBD and activates HIV-1 LTR by a  
mechanism that has been reported for RHA (Fujii et al., 2001).  
In  light  of  this  possibility,  RHA  and  DHX30 may  play  
redundant roles in HIV-1 gene transcription. This speculation  
helps to explain the observation that knockdown of DHX30 by  
small interfering RNA oligos did not affect HIV-1 LTR tran- 
scription  (Fig. 3)  simply  because  RHA  suffices  to  activate HIV- 
1 LTR in the absence of DHX30. 
Another  finding of  this study  is that overexpression of  
DHX30 decreases the levels of HIV-1 RNA packaging by as  
much as 10-fold (Fig. 5B). At this point, it is unclear to which  
extent the defective HIV-1 RNA packaging is attributed to the  
increased  steady-state  viral  RNA  seen  with  DHX30 over- 
expression. It is known that specific packaging of HIV-1 RNA  
into virus particles is governed by the high affinity of viral Gag  
protein for a stretch of viral RNA sequence that is located at the  
5′ un-translated region (UTR), named viral RNA packaging  
signals (Berkowitz et al., 1996). In this light, DHX30 may bind  
to the 5′ UTR RNA  region  and  modify  the  structures  of  the viral 
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RNA packaging signals in such a way that Gag protein is unable  
to properly recognize viral RNA. Other possibilities involve the  
observation that DHX30 is associated with the mitochondria  
and may participate in mitochondria DNA replication (Wang  
and Bogenhagen, 2006). One consequence of DHX30 over- 
expression is then the possible accumulation of DHX30 in the  
mitochondria and sequestration of HIV-1 RNA to this cellular  
organelle. This speculation is supported by a previous study  
showing  that  HIV-1 RNA  is  located  in  the  mitochondria  
(Somasundaran et al., 1994). Were DHX30 able to bind HIV-1  
RNA via its dsRBD, this helicase could be the factor that  
recognizes and recruits HIV-1 RNA to this cellular organelle.  
Alternatively, as a  mitochondria protein, overexpression  of  
DHX30 may promote replication of the mitochondria and thus  
stimulate ATP production. The increased ATP levels may ac- 
celerate  Gag  assembly  and  HIV-1 budding (Dooher  and  
Lingappa, 2004; Tritel and Resh, 2001), which leads to the  
release of large amount of viruses that have not had a chance to  
package viral RNA. 
In summary, DHX30 activates the transcription from HIV-1 
LTR to a moderate extent, and this activity of DHX30 may also be 
undertaken by other cellular RNA helicases such as RHA. 
Notably, overexpression of DHX30 drastically inhibits HIV-1 
RNA  packaging  as  well  as  virus  infection,  indicative  that 
DHX30 represents a potential anti-HIV factor that targets the 
process of viral RNA packaging. 
 
Materials and methods 
 
Plasmids and cloning 
 
The infectious HIV-1 cDNA clones BH10 and NL4-3 were  
utilized in the following experiments. The DHX30 (variant 1)  
cDNA was obtained from ATCC (ATCC number MGC-21290,  
Gene bank number BC020126). The HA (hemaglutanin) tag  
was attached to the C-terminus of DHX30 sequence by PCR  
using primers 5′-GTG GAA GCT TAT GTT CAG CCT GGA  
CTC ATT CAG-3′ (variant 1), 5′-CAT TAA GCT TAT GGC  
AGC TTC TAG GGA CCT ATT AAA AG-3′ (variant 2), and  
the reverse primer 5′-GAC ACG CGG CCG CTC AAG AGC  
GTA ATC TGG AAC ATC GTA TGG GTA GTC GTC AGC  
TGT CTT GCG CAC ATC-3′ (containing the HA tag). The  
PCR products were digested with restriction enzymes HindIII  
and NotI and inserted into the pcDNA3.1 vector (Invitrogen).  
These DNA  clones  were  named DHX30(v1)-HA and DHX30 
(v2)-HA. The DEVH motif of DHX30 was mutated to AAVH  
through use of a PCR-based method. In brief, the mutations  
were introduced in the first round of PCR with primers 5′-GAG  
CCA CGT CAT CGT GGC TGC GGT GCA TGA GCG GGA  
C-3′ and 5′-GGA AGC ACA GGA TCC CAC CTG-3′. The  
PCR products were used as a mega-primer in the second PCR  
together with the sense primer 5′-GAC TAA GCT TAT GGC  
AGC TTC TAG GGA CCT ATT AAA AG-3′. The final PCR  
products were digested with restriction enzymes HindIII and  
BamHI  and used to replace  the same  fragment in the DHX30 
(v2)-HA cDNA. The DNA clone thus created was named  
DHX30(AAVH)-HA. In  order to  generate the DHX30(v2)-RFP  
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DNA construct, the DHX30 DNA was amplified using primer  
pair 5′-CAT TAA GCT TAT GGC AGC TTC TAG GGA CCT  
ATT AAA AG-3′ and 5′-GAA GCG AAT TCC GTC GTC  
AGC TGT CTT GCG CAC ATC-3′, digested with restriction  
enzymes HindIII and EcoRI and inserted into the pDsRed2-N1  
vector (Clontech). The LTR-Luc and Tat-Flag DNA constructs  
were kindly provided by Dr John Hiscott (both the LTR and Tat  
sequences are derived from HIV-1 subtype B) (Roof et al.,  
2002). The GL3-Luc DNA was a gift of Dr Charles Brown  
(Rackham and Brown, 2004). 
 
Cell culture 
 
The 293T cells, HeLa cells and TZM-bl cells were grown in  
DMEM media supplemented with 10% fetal calf serum. The  
TZM-bl cells are derived from HeLa cells, express the CD4,  
CCR5 and CXCR4 surface markers and are stably transfected  
by HIV-1-LTR-Luc reporter DNA (Wei et al., 2002). TZM-bl  
cells were obtained from the NIH AIDS Research & Reference  
Reagent  Program.  Transfection  of 293T and  HeLa  cells  
were performed with Lipofectamine (Invitrogen) according to  
manufacturer's instruction. 
 
Short interfering RNA (siRNA) knockdown of DHX30 protein 
 
Two siRNA oligos named siDHX30-1 and siDHX30-2 were  
used to knockdown the endogenous DHX30. These two siRNA  
oligos target DHX30 mRNA  (NM_014966)  at  nucleotide  
positions 330 to 348 and 1133 to 1151, respectively. The control  
siRNA oligo (siCon) was purchased from Ambion (catalogue  
number AM4635). 293T cells were transfected with siRNA  
oligos (at a concentration 40 nM) twice using Lipofectamine,  
2000 (Invitrogen) followed by transfection with LTR-Luc and  
TK-RL reporter DNA clones. The DHX30-knockdown effi- 
ciency was monitored by determining the levels of DHX30  
mRNA in Northern blots. Expression of firefly luciferase and  
Renilla luciferase  was  measured  using  the Dual-Luciferase  
Reporter Assay System (Promega). 
 
Western blotting 
 
Forty-eight hours after transfection, cells were washed with  
1× phosphate buffered saline, spun down at 1000×g for 5 min at 
4 °C and lysed in cellular protein extraction buffer containing  
1% Nonidet P-40, 100 mM NaCl, 50 mM Tris-HCl (pH 7.5)  
and  protease  inhibitor  cocktail (Roche  Diagnostics).  After  
clarification at 13,000 rpm in a bench-top eppendorf centrifuge,  
the supernatants were subject to electrophoresis in SDS-PAGE.  
Proteins were then transferred to the PVDF membrane (Roche  
Diagnostics) and probed with primary antibodies including  
rabbit anti-p24 antibody (ID Lab Inc.), mouse anti-β -actin  
antibody (Sigma-Aldrich) and rabbit anti-HA antibody (Sigma- 
Aldrich). Following incubation with appropriate horseradish  
peroxidase-conjugated secondary antibodies (GE Healthcare  
UK Limited), the membranes were treated with the ECL reagent  
(Perkin Elmer). The protein signals were visualized by exposing  
to X-ray films. 
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Luciferase assay 
 
293T cells were seeded in 24-well plates and transfected the  
next day with 100 ng of the LTR-Luc DNA and various amounts  
of DHX30(v2)-HA DNA. Twenty-four hours after transfection,  
cells were lysed in 1× passive lysis buffer (Promega). Levels of the  
firefly luciferase and the Renilla luciferase activity were measured  
using the Dual-Luciferase Reporter Assay System (Promega). 
 
Measuring virus infectivity 
 
The amount of viruses in culture supernatants was deter- 
mined by measuring the levels of HIV-1 p24(CA) antigen using 
the HIV-1 antigen microelisa system (Vironostakia). TZM-bl 
cells were seeded in 24-well plate at a density of 4 × 10
4
 cells per 
well 1 day before infection. Viruses equivalent to 10 ng of p24 
were used to infect TZM-bl cell, each infection was performed in 
triplicate. Forty-eight hours after infection, cells were lysed in 1× 
passive lysis buffer (Promega), and levels of firefly lucif- 
erase  activity  in the cell  lysates  were measured using the 
Luciferase Assay kit (Promega). 
 
Viral RNA analysis 
 
Total RNA was extracted using Trizol (Invitrogen) from  
293T cells that had been transfected with the BH10 DNA. An  
amount of 15 μg of RNA was denatured at 65 °C for 15 min in a  
buffer containing 50% formamide and 1× MOPS followed by  
electrophoresis in 1% denaturing agarose gel with 18% (V/V)  
formaldehyde at 100 V for 3 h. After treatment with 0.1 N  
NaOH for 20 min and 0.3 M NaOAc (pH 5.2) for 20 min, RNA  
was  transferred  to  nylon  membranes (GE  Healthcare  UK  
Limited)  and  incubated  with [α-
32
P]  labeled  HIV-1 DNA  
probes (at nt 1 to 2000). After extensive washing with 1× SSC  
buffer containing 0.1% SDS, viral RNA signals were visualized  
by exposure to X-ray films. The same membrane was stripped  
off the radioactive signals by incubating in 0.5% SDS at 60 °C  
for 60 min and re-probed for cellular GAPDH mRNA using  
[α-
32
P] labeled probes that were amplified with primer pair 5′- 
GCA GGG GGG AGC CAA AAG GG-3′/5′-TGC CAG CCC  
CAG CGT CAA AG-3′. The levels of GAPDH mRNA served  
as controls for sample loading. 
In order to measure the levels of viral RNA packaged into  
virus particles, viruses equivalent to 25 ng of p24 were subject to  
RNA extraction followed by treatment with DNase I at a  
concentration of 1 unit/μl to degrade any HIV-1 DNA that might  
be a result of contamination by the BH10 plasmid DNA used in  
transfection. The DNase I was then inactivated at 65 °C for 
10 min. Viral RNA was reverse transcribed to cDNA with primer  
p960-A (5′-GTA TTT GTC TAC AGC CTT CTG-3′). The viral  
cDNA thus generated was quantified in real-time PCR with  
primers p675-S (5′-CCA GAG GAG CTC TCT CGA CGC AG- 
3′)/p960-A using the LightCycler FastStart DNA Master SYBR  
Green 1 kit (Roche Diagnostics) in the light cycler real-time PCR  
machine (Roche Diagnostics). The standard curve of the real- 
time PCR was created using a series of HIV-1 cDNA dilutions  
including 10
2
, 5 × 10
2
, 10
3
, 5 × 10
3
, 10
4
, 5 × 10
4
 and 10
5
 copies.  
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The  PCR  reactions  were  performed  with 0.5 μM primers  and 
3 mM  Mg
2+
 under  conditions of  95 °C  for 10 s,  60 °C  for 5 s and 
72 °C for 13 s. The possible contamination in the RNA samples by 
viral plasmid DNA BH10 was assessed in regular PCR with primer 
pair p675-S/p960-A. 
 
Immunostaining and confocal microscopy 
 
HeLa cells were transfected with the DHX30(v2)-RFP DNA  
followed by fixation with 3.7% formaldehyde for 20 min at  
room temperature and permeabilization with 0.1% Triton X-100  
for 10 min. Immunostaining was performed with mouse anti- 
fibrillarin antibody (dilution 1:500) (Abcam), mouse anti-SC35  
antibody (dilution 1:500) (Abcam)  and  mouse  anti-coilin  
antibody (dilution 1:200) (Abcam)  followed  by  incubation  
with Alex488 conjugated goat anti-mouse secondary antibodies  
(Invitrogen). The images were recorded using the PASCAL  
laser scanning confocal microscope (Zeiss). 
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